{
  "title": "New Patient Outcome Assessed in Psoriasis Biologic Trial - Medscape",
  "url": "https://www.medscape.com/viewarticle/move-toward-assessing-well-being-psoriasis-biologic-2025a1000rgw",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: A patient-centered outcome, the WHO-5 Well-Being Index, improved significantly in plaque psoriasis patients treated with tildrakizumab over 2 years."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN**: [SHIP NOW] Implement standardized PRO assessments like WHO-5 in clinical trials to validate therapeutic benefits beyond disease control metrics."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL**: ðŸ”´ URGENT - As chronic disease management shifts towards value-based care, ePRO solutions that capture holistic patient well-being will gain competitive advantage."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: While improved PRO scores demonstrate patient benefit, the delayed WHO-5 recovery in some patients despite skin clearance highlights challenges in predicting long-term mental health outcomes."
    }
  ],
  "model": "granite4:tiny-h"
}